Research Article
Pulmonary Artery Filling Defects in COVID-19 Patients Revealed Using CT Pulmonary Angiography: A Predictable Complication?
Table 1
Clinical features of 43 COVID-19 patients with CTPA.
| | Clinical features | Total () | Absence of pulmonary embolism () | Pulmonary embolism () | value |
| | | | | 0.284 | | Sex M/F | 22/21 | 16/12 | 6/9 | 0.289 | | BMI, median (IQR) | 24.5 (22.3-27.8) | 24.2 (22.2-28.1) | 25.5 (22.4-27.1) | 0.7 | | Days of hospitalization, median (IQR) | 13.5 (10.6-21) | 17 (11-26) | 11 (4.8-21) | 0.2 | | Signs and symptoms at the time of hospitalization, (%) | | | | | | Fever | 39 (91) | 26 (93) | 13 (87) | 0.510 | | Cough | 27 (63) | 16 (57) | 11 (73) | 0.300 | | Dyspnoea | 25 (58) | 16 (57) | 9 (60) | 0.858 | | Thoracic pain | 6 (14) | 2 (7) | 4 (27) | 0.082 | | Laboratory tests, median (IQR) | | | | | | D-dimers hospital admission, μg/l () | 1029 (598-1904) | 775 (533-1158) | 1650 (1319-4620) | 0.002 | | D-dimers CTPA, μg/l () | 1795 (1072-4451) | 1370 (901-2182) | 4000 (1647-9618) | 0.009 | | Mean D-dimers | 1412 (901-3738) | 1131 (802-1746) | 3719 (1798-6593) | 0.001 | | Enoxaparin treatment before CTPA, (%) | 34 (80) | 22 (79) | 12 (80) | 0.914 | | Enoxaparin dose | 8400 (3400) | 8700 (3430) | 7555 (3570) | 0.26 | | NIV, (%) | 18 (43) | 14 (50) | 4 (27) | 0.144 | | Oxygen therapy, (%) | 17 (39) | 11 (39) | 6 (40) | 0.964 | | Revised Geneva score, median (IQR) | 3 (2-5) | 2 (0-4) | 4 (3-6) | 0.013 | | Well’s score, median (IQR) | 1 (0-2) | 1 (0-2) | 2 (0-3) | 0.170 | | Smoke, (%) | 3 (7) | 1 (4) | 2 (13) | 0.237 |
|
|
